{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T14:04:51Z","timestamp":1773497091967,"version":"3.50.1"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1097\/ftd.0b013e3182a37a1e","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T07:10:41Z","timestamp":1380611441000},"page":"141-147","source":"Crossref","is-referenced-by-count":22,"title":["Limited Sampling Model for Advanced Mycophenolic Acid Therapeutic Drug Monitoring After Liver Transplantation"],"prefix":"10.1097","volume":"36","author":[{"given":"Pieter","family":"Langers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogier R.","family":"Press","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akin","family":"Inderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge C. L. M.","family":"Cremers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"den Hartigh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej G.","family":"Baranski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"van Hoek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210129","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00192309","article-title":"The design and development of an immunosuppressive drug, mycophenolate mofetil.","volume":"14","author":"Allison","year":"1993","journal-title":"Springer Semin Immunopathol"},{"key":"R2-3-20210129","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.TP.0000165118.00988.D7","article-title":"Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results.","volume":"80","author":"Reich","year":"2005","journal-title":"Transplantation"},{"key":"R3-3-20210129","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2004.00455.x","article-title":". Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation.","volume":"4","author":"Kiberd","year":"2004","journal-title":"Am J Transplant"},{"key":"R4-3-20210129","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0009-9120(00)00196-X","article-title":". A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients.","volume":"34","author":"Pillans","year":"2001","journal-title":"Clin Biochem"},{"key":"R5-3-20210129","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1053-2498(00)00191-1","article-title":". Mycophenolic acid concentrations are associated with cardiac allograft rejection.","volume":"19","author":"DeNofrio","year":"2000","journal-title":"J Heart Lung Transplant"},{"key":"R6-3-20210129","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1097\/00007890-200006150-00018","article-title":". The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection.","volume":"69","author":"Yamani","year":"2000","journal-title":"Transplantation"},{"key":"R7-3-20210129","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/lt.20124","article-title":". Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.","volume":"10","author":"Tredger","year":"2004","journal-title":"Liver Transpl"},{"key":"R8-3-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/FTD.0b013e318040ce0b","article-title":". Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration-time curve in adult patients undergoing liver transplant.","volume":"29","author":"Zicheng","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R9-3-20210129","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/jlts.2001.23356","article-title":". A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients.","volume":"7","author":"Wiesner","year":"2001","journal-title":"Liver Transpl"},{"key":"R10-3-20210129","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.intimp.2006.09.022","article-title":". Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.","volume":"6","author":"Bilbao","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"R11-3-20210129","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1600-6143.2004.00556.x","article-title":". Mycophenolate mofetil can be used as monotherapy late after liver transplantation.","volume":"4","author":"Moreno Planas","year":"2004","journal-title":"Am J Transplant"},{"key":"R12-3-20210129","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/lt.20210","article-title":"Mycophenolate mofetil monotherapy in liver transplantation: a single center experience.","volume":"10","author":"Fairbanks","year":"2004","journal-title":"Liver Transpl"},{"key":"R13-3-20210129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007890-199907270-00018","article-title":". A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.","volume":"68","author":"van Gelder","year":"1999","journal-title":"Transplantation"},{"key":"R14-3-20210129","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":". Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transplant"},{"key":"R15-3-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","article-title":". Therapeutic drug monitoring of mycophenolate mofetil in transplantation.","volume":"28","author":"van Gelder","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R16-3-20210129","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/01.tp.0000232697.38021.9a","article-title":". Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature.","volume":"82","author":"Arns","year":"2006","journal-title":"Transplantation"},{"key":"R17-3-20210129","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1185\/030079906X148481","article-title":"Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome.","volume":"22","author":"Kaplan","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R18-3-20210129","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/clinchem\/48.9.1497","article-title":". Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus.","volume":"48","author":"Pawinski","year":"2002","journal-title":"Clin Chem"},{"key":"R19-3-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00007691-200108000-00001","article-title":". Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion.","volume":"23","author":"Shaw","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R20-3-20210129","first-page":"120","article-title":"Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy.","volume":"17","author":"Filler","year":"2004","journal-title":"Transpl Int"},{"key":"R21-3-20210129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003088-200443040-00004","article-title":". Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients.","volume":"43","author":"Le Guellec","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R22-3-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00007691-200004000-00005","article-title":"Limited sampling strategy for mycophenolic acid area under the curve.","volume":"22","author":"Filler","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R23-3-20210129","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.clinthera.2005.04.004","article-title":"Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.","volume":"27","author":"Mardigyan","year":"2005","journal-title":"Clin Ther"},{"key":"R24-3-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00063030-200115010-00004","article-title":"Mycophenolate mofetil: suggested guidelines for use in kidney transplantation.","volume":"15","author":"Behrend","year":"2001","journal-title":"BioDrugs"},{"key":"R25-3-20210129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2125.2005.02398.x","article-title":". Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.","volume":"60","author":"Cremers","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R26-3-20210129","first-page":"531","article-title":"Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting.","volume":"33","author":"Proost","year":"1995","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R27-3-20210129","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","article-title":"Clinical pharmacokinetics of mycophenolate mofetil.","volume":"34","author":"Bullingham","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"R28-3-20210129","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance.","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"key":"R29-3-20210129","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10928-009-9136-6","article-title":". Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.","volume":"36","author":"de Winter","year":"2009","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R30-3-20210129","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1681\/ASN.2005101070","article-title":". Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.","volume":"17","author":"van Hest","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R31-3-20210129","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2036.2005.02364.x","article-title":". Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.","volume":"21","author":"Langers","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R32-3-20210129","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/FTD.0b013e31818162b9","article-title":". Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration.","volume":"30","author":"Langers","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R33-3-20210129","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.ftd.0000167885.17280.6f","article-title":". Determinants of mycophenolic acid levels after renal transplantation.","volume":"27","author":"Borrows","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R34-3-20210129","first-page":"3638","article-title":"Lou HX, et al..","volume":"22","author":"Yau","year":"2007","journal-title":"Is a standard fixed dose of mycophenolate mofetil ideal for all patients Nephrol Dial Transplant"},{"key":"R35-3-20210129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1600-6143.2005.01151.x","article-title":". Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.","volume":"6","author":"Borrows","year":"2006","journal-title":"Am J Transplant"},{"key":"R36-3-20210129","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2165\/00003088-200544100-00006","article-title":". Population pharmacokinetics of mycophenolic acid in renal transplant recipients.","volume":"44","author":"van Hest","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R37-3-20210129","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/S0041-1345(03)00762-0","article-title":". The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics.","volume":"35","author":"Kuriata-Kordek","year":"2003","journal-title":"Transplant Proc"},{"key":"R38-3-20210129","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1034\/j.1399-0012.2001.150607.x","article-title":". Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients.","volume":"15","author":"Cattaneo","year":"2001","journal-title":"Clin Transplant"},{"key":"R39-3-20210129","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1600-6143.2009.02668.x","article-title":". Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.","volume":"9","author":"Gaston","year":"2009","journal-title":"Am J Transplant"},{"key":"R40-3-20210129","doi-asserted-by":"crossref","first-page":"118S","DOI":"10.1016\/S0041-1345(03)00218-5","article-title":"Minimizing calcineurin inhibitor drugs in renal transplantation.","volume":"35","author":"Flechner","year":"2003","journal-title":"Transplant Proc"},{"key":"R41-3-20210129","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/lt.21170","article-title":". Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation.","volume":"13","author":"Creput","year":"2007","journal-title":"Liver Transpl"},{"key":"R42-3-20210129","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/01.TP.0000071522.74885.48","article-title":". Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients.","volume":"76","author":"Pfitzmann","year":"2003","journal-title":"Transplantation"},{"key":"R43-3-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00007691-200104000-00005","article-title":". Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.","volume":"23","author":"van Gelder","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R44-3-20210129","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/ndt\/14.3.706","article-title":". Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study.","volume":"14","author":"Smak Gregoor","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"R45-3-20210129","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s004670050021","article-title":"Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression.","volume":"14","author":"Filler","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"R46-3-20210129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/FTD.0b013e3180318c35","article-title":". Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.","volume":"29","author":"Patel","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R47-3-20210129","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1046\/j.1600-6143.2005.00779.x","article-title":". Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.","volume":"5","author":"Hesselink","year":"2005","journal-title":"Am J Transplant"},{"key":"R48-3-20210129","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1365-2036.2007.03514.x","article-title":". Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice.","volume":"26","author":"Langers","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R49-3-20210129","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/TP.0b013e31824ad60a","article-title":". Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal.","volume":"93","author":"Mourer","year":"2012","journal-title":"Transplantation"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3182a37a1e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:41:23Z","timestamp":1620952883000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201404000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3182a37a1e","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}